

CITATION REPORT

List of articles citing

Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries

DOI: 10.1007/s10067-018-3982-9

Clinical Rheumatology, 2018, 37, 1143-1152.

Source: <https://exaly.com/paper-pdf/69084889/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
11	Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq. <i>Open Access Rheumatology: Research and Reviews</i> , 2019 , 11, 1-9	2.4	
10	The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy. <i>Biomolecules</i> , 2019 , 9,	5.9	25
9	[Biosimilars in Internal Medicine: Needed in-depth knowledge to best prescribe]. <i>Revue De Medecine Interne</i> , 2019 , 40, 1-4	0.1	
8	Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. <i>Biomedicines</i> , 2020 , 8,	4.8	2
7	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. <i>Advances in Therapy</i> , 2020 , 37, 4491-4518	4.1	12
6	Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait. <i>Clinical Rheumatology</i> , 2021 , 40, 1759-1765	3.9	4
5	Biosimilars in India; Current Status and Future Perspectives. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2019 , 11, 12-15	1.1	8
4	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. <i>Drugs</i> , 2021 , 81, 1859-1879	1.1	3
3	Perception of Biosimilar Biologics and Non-Medical Prescription Switching among Rheumatologists: A Saudi Society for Rheumatology Initiative.. <i>Saudi Pharmaceutical Journal</i> , 2022 , 30, 39-44	4.4	0
2	Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?. <i>Patient Related Outcome Measures</i> , 2022 , 13, 79-95	2.9	
1	The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan. 2022 , 2022, 1-12		